976 related articles for article (PubMed ID: 30336540)
1. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
Dollinger MM; Behl S; Fleig WE
Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
[TBL] [Abstract][Full Text] [Related]
2. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer.
Battaglia P; Baritono E; Remo A; Vendraminelli R; Conti A
Tumori; 2014; 100(2):122-7. PubMed ID: 24852854
[TBL] [Abstract][Full Text] [Related]
3. Multitarget stool DNA testing for colorectal-cancer screening.
Imperiale TF; Ransohoff DF; Itzkowitz SH; Levin TR; Lavin P; Lidgard GP; Ahlquist DA; Berger BM
N Engl J Med; 2014 Apr; 370(14):1287-97. PubMed ID: 24645800
[TBL] [Abstract][Full Text] [Related]
4. Multi-target stool DNA test in the surveillance of inflammatory bowel disease: a cross-sectional cohort study.
Klepp P; Kisiel JB; Småstuen MC; Røseth A; Andersen SN; Vatn MH; Ahlquist DA; Moum BA; Brackmann S
Scand J Gastroenterol; 2018 Mar; 53(3):273-278. PubMed ID: 29313389
[TBL] [Abstract][Full Text] [Related]
5. Options for screening for colorectal cancer.
Atkin W
Scand J Gastroenterol Suppl; 2003; (237):13-6. PubMed ID: 12797674
[TBL] [Abstract][Full Text] [Related]
6. Fecal Genetic Mutations and Human DNA in Colorectal Cancer and Polyps Patients.
Lima J; Teixeira Y; Pimenta C; Felipe AV; Silva TD; Junior EEDL; Saad SS; Deak E; Murray H; Manoukian Forones N
Asian Pac J Cancer Prev; 2019 Oct; 20(10):2929-2934. PubMed ID: 31653137
[TBL] [Abstract][Full Text] [Related]
7. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay.
Zou H; Taylor WR; Harrington JJ; Hussain FT; Cao X; Loprinzi CL; Levine TR; Rex DK; Ahnen D; Knigge KL; Lance P; Jiang X; Smith DI; Ahlquist DA
Gastroenterology; 2009 Feb; 136(2):459-70. PubMed ID: 19026650
[TBL] [Abstract][Full Text] [Related]
8. Results of National Colorectal Cancer Screening Program in Croatia (2007-2011).
Katičić M; Antoljak N; Kujundžić M; Stamenić V; Skoko Poljak D; Kramarić D; Stimac D; Strnad Pešikan M; Samija M; Ebling Z
World J Gastroenterol; 2012 Aug; 18(32):4300-7. PubMed ID: 22969192
[TBL] [Abstract][Full Text] [Related]
9. Controversies in colorectal cancer screening.
Pox CP
Digestion; 2014; 89(4):274-81. PubMed ID: 25034478
[TBL] [Abstract][Full Text] [Related]
10. Gene expression analysis using a highly sensitive DNA microarray for colorectal cancer screening.
Koga Y; Yamazaki N; Takizawa S; Kawauchi J; Nomura O; Yamamoto S; Saito N; Kakugawa Y; Otake Y; Matsumoto M; Matsumura Y
Anticancer Res; 2014 Jan; 34(1):169-76. PubMed ID: 24403458
[TBL] [Abstract][Full Text] [Related]
11. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer.
Mulder SA; van Leerdam ME; van Vuuren AJ; Francke J; van Toorenenbergen AW; Kuipers EJ; Ouwendijk RJ
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):878-82. PubMed ID: 17873612
[TBL] [Abstract][Full Text] [Related]
12. Patient perceptions of stool-based DNA testing for colorectal cancer screening.
Schroy PC; Heeren TC
Am J Prev Med; 2005 Feb; 28(2):208-14. PubMed ID: 15710277
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of screening strategies for colorectal cancer.
Barzi A; Lenz HJ; Quinn DI; Sadeghi S
Cancer; 2017 May; 123(9):1516-1527. PubMed ID: 28117881
[TBL] [Abstract][Full Text] [Related]
14. Colorectal cancer screening: comparison of transferrin and immuno fecal occult blood test.
Chen JG; Cai J; Wu HL; Xu H; Zhang YX; Chen C; Wang Q; Xu J; Yuan XL
World J Gastroenterol; 2012 Jun; 18(21):2682-8. PubMed ID: 22690078
[TBL] [Abstract][Full Text] [Related]
15. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
Quintero E
Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
[TBL] [Abstract][Full Text] [Related]
16. A combination of faecal tests for the detection of colon cancer: a new strategy for an appropriate selection of referrals to colonoscopy? A prospective multicentre Italian study.
Parente F; Marino B; Ilardo A; Fracasso P; Zullo A; Hassan C; Moretti R; Cremaschini M; Ardizzoia A; Saracino I; Perna F; Vaira D
Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1145-52. PubMed ID: 22735608
[TBL] [Abstract][Full Text] [Related]
17. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
[TBL] [Abstract][Full Text] [Related]
18. Power of screening tests for colorectal cancer enhanced by high levels of M2-PK in addition to FOBT.
Zaccaro C; Saracino IM; Fiorini G; Figura N; Holton J; Castelli V; Pesci V; Gatta L; Vaira D
Intern Emerg Med; 2017 Apr; 12(3):333-339. PubMed ID: 28155016
[TBL] [Abstract][Full Text] [Related]
19. Faecal biomarkers do not always identify pre-cancerous lesions in patients who present in primary care with bowel symptoms.
Keenan J; Aitchison A; Leaman J; Pearson J; Frizelle F
N Z Med J; 2019 Aug; 132(1501):48-56. PubMed ID: 31465327
[TBL] [Abstract][Full Text] [Related]
20. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
Caviglia GP; Cabianca L; Fagoonee S; Gili FM
Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
